C2N Diagnostics, a world leader in advanced brain health diagnostics, has reached an exceptional new milestone with the submission of its innovative, accessible blood test to the U.S. Food and Drug ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a ...
StockStory.org on MSN
1 Mid-Cap Stock to Target This Week and 2 We Turn Down
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract ...
The Trump administration has restored almost all of the 500 National Institutes of Health grants it suspended at UCLA in July in response to a federal judge's order last week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback